AI Engines For more Details: Perplexity Kagi Labs You
Antiretroviral Activity: Abacavir works by inhibiting the activity of HIV reverse transcriptase, an enzyme necessary for the replication of the HIV virus. By interfering with the replication of HIV genetic material, abacavir helps suppress viral replication and reduce HIV viral load in the bloodstream.
Management of HIV Infection: Abacavir sulfate is indicated for the treatment of HIV-1 infection in combination with other antiretroviral medications. It is used as part of highly active antiretroviral therapy (HAART), also known as combination antiretroviral therapy (cART), to control HIV replication, improve immune function, and delay the progression of HIV-related complications.
Boosting Immune Function: By reducing HIV viral load and preventing further damage to the immune system, abacavir therapy helps restore immune function and reduce the risk of opportunistic infections and HIV-related malignancies. It can also increase CD4+ T-cell counts, which are a measure of immune system health.
Prevention of HIV Transmission: Effective antiretroviral therapy, including abacavir sulfate, can significantly reduce the risk of HIV transmission from infected individuals to their sexual partners and unborn children. Treatment adherence and viral suppression are essential for achieving optimal outcomes in HIV prevention and treatment efforts.
Once-Daily Dosage: Abacavir sulfate is typically administered orally in the form of tablets or a solution. The recommended dosage for adults and adolescents weighing 25 kg or more is typically 600 mg (or two 300 mg tablets) taken once daily with or without food. The dosage may be adjusted based on individual patient factors, such as renal function, concomitant medications, and treatment history.
Hypersensitivity Reactions: A significant concern associated with abacavir sulfate is the risk of hypersensitivity reactions, which can be severe or life-threatening if not promptly recognized and managed. Hypersensitivity reactions to abacavir typically occur within the first few weeks of treatment initiation and may manifest as fever, rash, gastrointestinal symptoms (such as nausea, vomiting, abdominal pain), respiratory symptoms (such as dyspnea, cough), and constitutional symptoms (such as fatigue, malaise).
HLA-B*5701 Screening: Prior to initiating abacavir therapy, patients should undergo screening for the HLA-B5701 allele, which is strongly associated with an increased risk of abacavir hypersensitivity reactions. Individuals who test positive for HLA-B5701 should not receive abacavir unless the potential benefits outweigh the risks, and alternative antiretroviral therapy options should be considered.
Lactic Acidosis and Hepatic Steatosis: Like other NRTIs, abacavir sulfate may be associated with metabolic complications such as lactic acidosis (elevated lactate levels in the blood) and hepatic steatosis (fatty liver disease). These adverse effects are rare but can be serious, particularly in patients with pre-existing risk factors such as obesity, diabetes, or hepatic dysfunction.
Drug Interactions: Abacavir sulfate may interact with other medications, including other antiretroviral drugs, that are metabolized by the cytochrome P450 enzyme system or that affect renal function. Clinicians should carefully consider potential drug interactions and monitor patients for adverse effects or changes in therapeutic efficacy when prescribing abacavir in combination with other medications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.9 | 0.6 | 0.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.3 | 3 |
| Allergies | 1.5 | 1.2 | 0.25 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.5 | 2.6 | -0.73 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.3 | 3.33 |
| Ankylosing spondylitis | 2 | 0.9 | 1.22 |
| Anorexia Nervosa | 0.6 | 1.5 | -1.5 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 2.3 | 0.9 | 1.56 |
| Atherosclerosis | 0.6 | 0.3 | 1 |
| Atrial fibrillation | 2.3 | 0.5 | 3.6 |
| Autism | 4.2 | 3 | 0.4 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.9 | 1.2 | -0.33 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Cancer (General) | 0.6 | 0.1 | 5 |
| Carcinoma | 2 | 1.5 | 0.33 |
| Celiac Disease | 1.2 | 2.1 | -0.75 |
| Cerebral Palsy | 0.9 | 0.6 | 0.5 |
| Chronic Fatigue Syndrome | 2.5 | 3.5 | -0.4 |
| Chronic Kidney Disease | 2 | 1.2 | 0.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.2 | -0.2 |
| Chronic Urticaria (Hives) | 0.6 | 0.3 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.6 | -1 |
| Cognitive Function | 1.5 | 0.6 | 1.5 |
| Colorectal Cancer | 2.2 | 0.3 | 6.33 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 0.6 | 1.2 | -1 |
| COVID-19 | 2.6 | 3.9 | -0.5 |
| Crohn's Disease | 2.6 | 2.2 | 0.18 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.3 | 0.9 | -2 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 4.1 | 3.7 | 0.11 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.5 | 0.2 |
| Endometriosis | 1.4 | 1.5 | -0.07 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 0.6 | 0.3 | 1 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.9 | 1.1 | -0.22 |
| Functional constipation / chronic idiopathic constipation | 1.7 | 1.7 | 0 |
| gallstone disease (gsd) | 1.2 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.6 | -1 |
| Generalized anxiety disorder | 1.2 | 0.9 | 0.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.3 | 2 |
| Graves' disease | 0.9 | 2 | -1.22 |
| Gulf War Syndrome | 0.6 | 0.2 | 2 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.1 | 1.2 | 0.75 |
| Heart Failure | 1.3 | 0.3 | 3.33 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0 | 0 |
| hyperglycemia | 0.8 | 0.3 | 1.67 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 2.4 | 1.7 | 0.41 |
| Hypothyroidism | 0 | 0.6 | 0 |
| Hypoxia | 0.9 | 0.9 | |
| IgA nephropathy (IgAN) | 1.2 | 0.8 | 0.5 |
| Inflammatory Bowel Disease | 1.4 | 2.6 | -0.86 |
| Insomnia | 1.9 | 1.5 | 0.27 |
| Intelligence | 0.6 | 0.2 | 2 |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 2.5 | 1.8 | 0.39 |
| ischemic stroke | 1.2 | 0.3 | 3 |
| Liver Cirrhosis | 2.8 | 2.7 | 0.04 |
| Long COVID | 3.1 | 2.6 | 0.19 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.9 | -0.9 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.9 | 1.5 | -0.67 |
| ME/CFS without IBS | 0.7 | 1.5 | -1.14 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0 | 0 |
| Metabolic Syndrome | 2.3 | 2.4 | -0.04 |
| Mood Disorders | 3.5 | 2.8 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 1.8 | 2.1 | -0.17 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | 0.8 | -1.67 |
| Neuropathy (all types) | 0.6 | 0.2 | 2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 1.5 | 0.53 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 4.7 | 3.6 | 0.31 |
| obsessive-compulsive disorder | 1.5 | 2.6 | -0.73 |
| Osteoarthritis | 0.6 | 0.9 | -0.5 |
| Osteoporosis | 1.2 | 1.2 | 0 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.2 | 2.8 | 0.14 |
| Polycystic ovary syndrome | 1.5 | 1.5 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 1.2 | 0.3 | 3 |
| Primary sclerosing cholangitis | 0.9 | 0.6 | 0.5 |
| Psoriasis | 1.5 | 0.8 | 0.88 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.5 | 1.7 | 1.06 |
| Rosacea | 0.9 | 0.9 | |
| Schizophrenia | 2.4 | 1.5 | 0.6 |
| scoliosis | 0.3 | 0.4 | -0.33 |
| Sjögren syndrome | 1.1 | 0.9 | 0.22 |
| Sleep Apnea | 1.5 | 1.2 | 0.25 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.7 | 0.29 |
| Systemic Lupus Erythematosus | 1.7 | 1.2 | 0.42 |
| Tic Disorder | 0.9 | 0.8 | 0.13 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1.5 | 1.2 | 0.25 |
| Type 2 Diabetes | 3 | 2.2 | 0.36 |
| Ulcerative colitis | 1.7 | 1.6 | 0.06 |
| Unhealthy Ageing | 3.2 | 0.6 | 4.33 |
| Vitiligo | 1.2 | 0.6 | 1 |
